Skip to main content
    N

    Neuphoria Therapeutics Inc (NEUP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.27
    -0.21 (-8.47%)

    Market Cap: $13.42M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Neuphoria Therapeutics Inc (NEUP) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Neuphoria Therapeutics (NEUP) has a market cap of $13.42M. Its share count is up 140.92% from a year earlier. It holds $18.74M more cash than debt, 139.67% of its market cap.

    Total Valuation

    Market Cap$13.42M
    Latest price (Nov 17, 2026)$2.27

    Key Dates

    The next earnings report is expected on Nov 18, 2026, covering the quarter ending Sep 30, 2026.

    Next Earnings DateNov 18, 2026 (expected)
    Last Earnings DateSep 2, 2026
    Fiscal Year EndJune

    Share Statistics

    Shares Outstanding5.41M
    Shares Change (YoY)+140.92%

    Valuation Ratios

    P/B Ratio0.5x
    P/TBV Ratio0.8x

    Price Statistics

    The stock is down 52.61% over 52 weeks and trades 31.42% below its 50-day average.

    Beta (1Y)0.83
    52-Week Change-52.61%
    1-Month Change-31.42%
    3-Month Change-42.24%
    6-Month Change-52.41%
    Total Return (1Y)-52.61%
    Return vs SPY (1Y)-63.67%
    Max Drawdown (1Y)-58.58%
    Sharpe Ratio (1Y)-1.41
    Correlation with SPY (1Y)0.22
    50-Day Average$3.31
    200-Day Average$4.08
    52-Week Range$2.45 to $5.53
    RSI (14 Days)10.7
    Average Volume (20 Days)33.66K

    Financial Position

    Current assets cover 18.05x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio18.05x
    Quick Ratio18.05x
    Debt / Equity0.00x

    Returns and Efficiency

    ROE (5Y Average)-56.12%
    ROA (5Y Average)-42.47%
    ROIC (5Y Average)-30.40%

    Scores

    NEUP has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Balance Sheet

    Shareholder equity funds 86.57% of the $27.11M in total assets.

    Cash and Equivalents$18.74M
    Total Debt$0
    Net Cash$18.74M
    Net Cash Per Share$3.46
    Working Capital$18.52M
    Shareholder Equity$23.47M
    Book Value Per Share$4.34
    Tangible Book Value$15.97M
    Tangible Book Per Share$2.95
    Total Assets$27.11M
    Total Liabilities$3.63M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$10.22M
    FCF Per Share-$1.89
    Depreciation and Amortization$662.85K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Stock Splits

    The last split was a 1-for-12 reverse split on Dec 27, 2024.

    Last Split DateDec 27, 2024
    Split TypeReverse split
    Split Ratio1:12

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About NEUP

    What is NEUP's market cap?

    Neuphoria Therapeutics has a market cap of $13.42M.

    How many shares of NEUP are outstanding?

    Neuphoria Therapeutics has 5.41M shares outstanding. The count is up 140.92% from a year earlier.

    Does NEUP pay a dividend?

    No. Neuphoria Therapeutics does not pay a dividend.

    How much debt does NEUP have?

    Neuphoria Therapeutics has $0 of total debt and $18.74M of cash and equivalents, a net cash position of $18.74M.